The present technology is generally related to coupon assays for determining the likelihood of developing thrombus when receiving an implantable medical device.
Implantable blood pumps, such as Ventricular Assist Devices (VADs), survivability at two years is comparable to that of transplanted hearts, but VAD patients have a considerably higher incidence of thrombo-embolic adverse events. VAD patient medications, for example, anti-coagulants, are titrated based on prothrombin time (PT), which is a test used to help detect and diagnose a bleeding disorder or excessive clotting disorder. An international normalized ratio (INR) is calculated from a PT result and is utilized to monitor the effectiveness of blood-thinning medication. However, some VAD patients experience thrombo-embolic events while others have bleeding complications, although both groups may have the same INR levels.
The techniques of this disclosure generally relate to coupon assays for determining the likelihood of developing thrombus when receiving an implantable blood pump.
In one aspect, the present disclosure provides a method for determining a patient's likelihood of experiencing a thromboembolic event when receiving an implantable blood contacting medical device. The method includes extracting a sample of blood from the patient. The sample of blood is exposed to a metal, metal alloy, or ceramic in a test tube. The sample of the blood is agitated in the test tube. A thromboembolic marker for the sample in the test tube is measured. If the thromboembolic marker for the sample in the test tube is higher than a predetermined thromboembolic marker threshold, it is determined that the patient is likely to experience the thromboembolic event when receiving the blood contacting implantable medical device.
In another aspect of this embodiment, the sample of blood is 5 ml or less.
In another aspect of this embodiment, the sample of blood is agitated on a roller for a predetermined period of time.
In another aspect of this embodiment, the predetermined period of time is 5, 30, or 60 minutes.
In another aspect of this embodiment, the sample of blood is extracted before the patient receives the implantable medical device.
In another aspect of this embodiment, the sample of blood is extracted after the patient receives the implantable medical device.
In another aspect of this embodiment, the thromboembolic marker threshold is an average thromboembolic marker level measured from a plurality of donor samples exposed to the metal, metal alloy, or ceramic and agitated for a predetermined period of time.
In another aspect of this embodiment, the metal, metal alloy, or ceramic is Titanium or Titanium Nitride.
In another aspect of this embodiment, the method further includes measuring a thromboembolic marker level of a second sample of blood from the patient in fluid communication with an implantable medical device and comparing the measured thromboembolic marker level of the second sample with the sample of blood exposed to the metal, metal alloy, or ceramic.
In another aspect of this embodiment, the method further includes determining that the measured thromboembolic marker levels in the second sample of blood is indicative or not indicative of the likelihood of experiencing the thromboembolic event when receiving the blood contacting implantable medical device based on the comparison.
In one aspect, a method for determining a patient's likelihood for experiencing a thromboembolic event when receiving an implantable blood pump includes extracting a plurality of samples of blood from the patient. The plurality of samples of blood is separately exposed to titanium (Ti) and titanium nitride (TiN) in respective test tubes. Each of the plurality of samples of the blood in the respective test tubes is agitated. Thrombin-antithrombin complex (TAT) levels are measured for each of the plurality of samples in the respective test tubes. If the TAT levels in the respective test tubes containing Ti and TiN are higher than predetermined TAT thresholds for Ti and TiN exposed blood in respective test tubes, it is determined that the patient is likely to experience the thromboembolic event when receiving the implantable blood pump.
In another aspect of this embodiment, each of the plurality of samples of blood is 5 ml or less.
In another aspect of this embodiment, each of the plurality of samples of blood is agitated on a roller for a predetermined period of time.
In another aspect of this embodiment, the predetermined period of time is one of 5 minutes, 30 minutes, or 60 minutes.
In another aspect of this embodiment, the plurality of samples of blood is extracted before the patient receives the implantable blood pump.
In another aspect of this embodiment, the plurality of samples of blood is extracted after the patient receives the implantable blood pump.
In another aspect of this embodiment, the predetermined TAT threshold for Ti and TiN exposed blood is an average TAT level measured from a plurality of donor samples exposed to Ti and TiN and agitated for a predetermined period of time.
In another aspect of this embodiment, the method further includes measuring a TAT level of a second sample of blood from the patient in fluid communication with an implantable blood pump and comparing the measured TAT level of the second sample with the plurality of samples of blood exposed to Ti and TiN.
In another aspect of this embodiment, the method further includes determining that the measured TAT levels in the second sample of blood is indicative or not indicative of a likelihood of experiencing the thromboembolic event when receiving the implantable blood pump based on the comparison.
In one aspect, a method for determining a patient's likelihood for experiencing a thromboembolic event when receiving an implantable blood pump includes extracting a plurality of samples of blood from the patient. The plurality of samples of blood is exposed separately to titanium (Ti) and titanium nitride (TiN) in respective test tubes, a volume of blood in the respective test tubes being selected to maximize a surface area of the Ti and TiN exposed to blood. Each of the plurality of samples of the blood in the respective test tubes is agitated on a plurality of rollers for 60 minutes. Thrombin-antithrombin complex (TAT) levels for each of the plurality of samples in the respective test tubes is measured. If the TAT levels in the respective test tubes containing Ti and TiN are higher than predetermined TAT thresholds for Ti and TiN exposed blood in respective test tubes, it is determined that the patient is likely to experience a thromboembolic event when receiving the implantable blood pump.
The details of one or more aspects of the disclosure are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the techniques described in this disclosure will be apparent from the description and drawings, and from the claims.
A more complete understanding of the present invention, and the attendant advantages and features thereof, will be more readily understood by reference to the following detailed description when considered in conjunction with the accompanying drawings wherein:
It should be understood that various aspects disclosed herein may be combined in different combinations than the combinations specifically presented in the description and accompanying drawings. It should also be understood that, depending on the example, certain acts or events of any of the processes or methods described herein may be performed in a different sequence, may be added, merged, or left out altogether (e.g., all described acts or events may not be necessary to carry out the techniques). In addition, while certain aspects of this disclosure are described as being performed by a single module or unit for purposes of clarity, it should be understood that the techniques of this disclosure may be performed by a combination of units or modules associated with, for example, a medical device.
Referring now to
In an exemplary method, one or more samples of blood, for example, 5 ml or less per sample is extracted from a donor patient (Step 102). The donor patient may have an implanted medical device when the sample is extracted, or may receive one after the sample is extracted. Each sample of blood may be placed in a test tube for further examination. For example, as shown in
An example of the results from a plurality of sample donors is shown in
Referring now to
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described herein above. In addition, unless mention was made above to the contrary, it should be noted that all of the accompanying drawings are not to scale. A variety of modifications and variations are possible in light of the above teachings without departing from the scope and spirit of the invention, which is limited only by the following claims.
Example 1. A method for determining a patient's likelihood of experiencing a thromboembolic event when receiving an implantable blood contacting medical device, the method comprising:
Example 2. The method of Example 1, wherein the sample of blood is 5 ml or less.
Example 3. The method of Example 1, wherein the sample of blood is agitated on a roller for a predetermined period of time.
Example 4. The method of Example 3, wherein the predetermined period of time is 5, 30, or 60 minutes.
Example 5. The method of Example 1, wherein the sample of blood is extracted before the patient receives the implantable medical device.
Example 6. The method of Example 1, wherein the sample of blood is extracted after the patient receives the implantable medical device.
Example 7. The method of Example 1, wherein the thromboembolic marker threshold is an average thromboembolic marker level measured from a plurality of donor samples exposed to the metal, metal alloy, or ceramic and agitated for a predetermined period of time.
Example 8. The method of Example 1, wherein the metal, metal alloy, or ceramic is Titanium, Titanium Nitride or Zirconia.
Example 9. The method of Example 1, further including:
Example 10. The method of Example 9, further including determining that the measured thromboembolic marker levels in the second sample of blood is indicative or not indicative of the likelihood of experiencing the thromboembolic event when receiving the blood contacting implantable medical device based on the comparison.
Example 11. A method for determining a patient's likelihood for experiencing a thromboembolic event when receiving an implantable blood pump, the method comprising:
Example 12. The method of Example 11, wherein each of the plurality of samples of blood is 5 ml or less.
Example 13. The method of Example 11, wherein each of the plurality of samples of blood is agitated on a roller for a predetermined period of time.
Example 14. The method of Example 13, wherein the predetermined period of time is one of 5 minutes, 30 minutes, or 60 minutes.
Example 15. The method of Example 11, wherein the predetermined TAT threshold for Ti and TiN exposed blood is an average TAT level measured from a plurality of donor samples exposed to Ti and TiN and agitated for a predetermined period of time.
Example 16. The method of Example 11, further including:
Example 17. The method of Example 16, further including determining that the measured TAT levels in the second sample of blood is indicative or not indicative of a likelihood of experiencing the thromboembolic event when receiving the implantable blood pump based on the comparison.
Example 18. A method for determining a patient's likelihood for experiencing a thromboembolic event when receiving an implantable blood pump, the method comprising:
Example 19. A kit for determining a patient's likelihood of experiencing a thromboembolic event when receiving an implantable blood contacting medical device, the kit comprising:
Example 20. The kit of Example 19, further including an anticoagulant in the test tube, and wherein the anticoagulant has a concentration in the test tube when exposed to blood of between 0.6 units per mL to 2 units per mL of blood.
Various examples have been described. These and other examples are within the scope of the following claims.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2022/014644 | 2/1/2022 | WO |
Number | Date | Country | |
---|---|---|---|
63144017 | Feb 2021 | US |